Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions: brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution; Drug · Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2036
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Glaucoma, Intraocular Pressure, Optic Neuropathy
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma and Ocular Hypertension
Interventions: Brimonidine Tartrate 0.025%, Vehicle; Drug
Lead sponsor: Eye Therapies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Winchester, Massachusetts

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions: Glaucoma and Cataract Surgery; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Open-Angle Glaucoma
Interventions: VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT); Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more

Conditions: Open Angle Glaucoma
Interventions: Cosopt, Xalatan; Drug
Lead sponsor: Advanced Glaucoma Specialists; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Reading, Massachusetts

Conditions: Glaucoma, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma
Interventions: Ahmed FP7 Valve, Baerveldt-350 Tube; Device
Lead sponsor: Credit Valley EyeCare; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 3
States / cities: Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 40
States / cities: Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: NCX 470 0.1%, Latanoprost 0.005%; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 63
States / cities: Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more

Conditions: Glaucoma
Interventions: glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Nanodropper adaptor, control; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glaucoma, Retinal Disease, Corneal Disease
Interventions: Nidek Mirante, Optovue RTVue XR Avanti, Optos P200DTx; Device
Lead sponsor: Nidek Co. LTD.; Industry
Eligibility: 22 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Visual Field Defect, Peripheral
Interventions: VisuALL, Humphrey Visual Field; Device
Lead sponsor: Duke University; Other
Eligibility: 4 Years to 21 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ocular Hypertension, Glaucoma
Interventions: AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Artesia, California

Conditions: Normal Tension Glaucoma
Interventions: Netarsudil, Brimonidine; Drug
Lead sponsor: Westlake Eye Specialists; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Austin, Texas • Killeen, Texas • Kyle, Texas + 1 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more

Conditions: Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions: H-1337 1.0%; Drug
Lead sponsor: D. Western Therapeutics Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma
Interventions: Perimetric test; Diagnostic Test
Lead sponsor: Envision Health Technologies, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glaucoma
Interventions: SENSIMED Triggerfish; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open Angle Glaucoma
Interventions: Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Prairie Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Glaucoma
Interventions: Yutiq 0.18 MG Drug Implant; Drug
Lead sponsor: Sanjay Asrani; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

Comparing Rates of Glaucoma in Professional Wind Versus Non-Wind Instrument Players

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

How Does Your Genetic Make-up (Profile) Influence Your Glaucoma?

IOP and Medication Reduction in MIGS Procedures

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Agreement and Precision Study of the Nidek Mirante

Virtual Reality Visual Field Testing as an Alternative in Childhood Eye Disease

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Open-Label Study of Safety of H1337 in Healthy Volunteers

Perimetric Testing With Virtual Reality

SENSIMED Triggerfish Safety and Tolerability

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery